GLP-1 and gastroparesis: what the FDA label actually says

The claim going around

Several health sites are pushing a story about a “March 2026 FDA label update” that supposedly added a gastroparesis warning to GLP-1 drugs, complete with a June 15, 2026 compliance deadline. We couldn’t confirm it against any primary FDA source. Not on fda.gov, not on accessdata.fda.gov, not in the label text itself.

That doesn’t mean the gastroparesis conversation is empty. There’s real label language and one real study. Neither supports the “new 2026 warning” framing. Here’s what we verified, pulled directly from the current Zepbound (tirzepatide) prescribing information, Reference ID 5751110, revised 02/2026.

What the label actually says

Section 5.2 of the Zepbound label states: “ZEPBOUND is not recommended in patients with severe gastroparesis.” That’s the whole sentence. It warns against giving the drug to people who already have severe gastroparesis. It doesn’t say the drug causes it.

The sentence isn’t new. It has appeared in tirzepatide labeling since earlier approvals. The “Recent Major Changes” table in the 02/2026 label revision lists one gastrointestinal-related update: a revision to “Severe Gastrointestinal Adverse Reactions (5.2).” The same table notes removal of a suicidal ideation subsection and of a KwikPen-sharing warning that was added back in 01/2026. Nothing in that table introduces gastroparesis wording this year.

So the sentence being cited as evidence of a “new 2026 warning” predates 2026.

Gastroparesis is not listed as a reported side effect

Section 6.2, Postmarketing Experience, lists the gastrointestinal events reported after approval: acute pancreatitis, hemorrhagic and necrotizing pancreatitis (sometimes fatal), ileus, intestinal obstruction, and severe constipation including fecal impaction. Gastroparesis isn’t there. It shows up only in the “not recommended” caution in Section 5.2, not as a confirmed adverse reaction with an estimated frequency.

The distinction matters. A postmarketing listing means the FDA received reports and is disclosing them, even without proof of causation. Gastroparesis hasn’t cleared that bar in the current label.

The mechanism: delayed gastric emptying is not the same as gastroparesis

Section 12.2 (Pharmacodynamics) states: “Tirzepatide delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time.” That’s the pharmacology that makes these drugs work. Slower stomach emptying contributes to fullness and reduced appetite. The label describes the effect as dose-dependent and time-limited, not permanent or progressive. Gastroparesis is a distinct, diagnosed medical condition. The label treats the two as related but separate.

The same mechanism drives a separate flag in Section 5.9: pulmonary aspiration risk during general anesthesia or deep sedation, since food can sit in the stomach longer than usual. The label is direct about the evidence gap here too, stating that “available data are insufficient to inform recommendations to mitigate the risk,” including whether changing fasting rules or pausing the drug before surgery would help. If you take a GLP-1 or GIP drug and have a sedation procedure coming up, tell the anesthesia team in advance.

What the Medication Guide tells patients to do

The patient-facing Medication Guide, also revised 02/2026, instructs patients to tell their provider before starting the drug if they “have severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems with digesting food.” That’s framed as a pre-existing condition to disclose, not a new risk the drug is confirmed to cause. If you already have gastroparesis, your provider needs to know before you start.

The actual study behind the risk numbers

The strongest evidence connecting semaglutide to gastroparesis doesn’t come from the FDA. It’s a retrospective cohort study built on Merative MarketScan claims data from 2018 to 2022, covering 55,460 people with obesity but without type 2 diabetes: 36,990 on semaglutide, 7,369 on bupropion-naltrexone, and 11,101 who had sleeve gastrectomy.

Gastroparesis incidence ran 6.5 per 1,000 person-years with semaglutide, versus 2.1 per 1,000 with bupropion-naltrexone and 1.1 per 1,000 with sleeve gastrectomy. After adjusting for baseline differences between groups, semaglutide carried a higher risk than bupropion-naltrexone (adjusted hazard ratio 3.33, 95% CI 2.27-4.98) and than sleeve gastrectomy (adjusted hazard ratio 6.14, 95% CI 3.94-9.57).

Both things are true at once. The relative risk is elevated, three to six times higher depending on the comparison. And the absolute incidence is low across all three groups, well under 1% per year even in the highest-risk group. A hazard ratio of 3.33 sounds alarming in isolation. Applied to a baseline rate of 2.1 per 1,000 person-years, it still adds up to a small number of affected people.

Where this study falls short of “proof”

This is one retrospective cohort study. Not a randomized trial, not an FDA analysis. It identified gastroparesis cases through insurance diagnosis codes rather than confirmatory gastric-emptying tests, so misclassification is possible in either direction. It compared semaglutide against two specific alternatives, bupropion-naltrexone and bariatric surgery, not against no treatment or the general population. If you’re not choosing between those three options, it can’t tell you your absolute risk. And the dataset is semaglutide only. Nothing here was directly tested for tirzepatide, the drug in Zepbound and Mounjaro. Extending these findings to tirzepatide would be a guess, not a finding.

The trial data on severe GI reactions

In the Zepbound clinical trial program (Studies 1 and 2, pooled N=2,519), severe gastrointestinal adverse reactions occurred in 1.7% of patients on the 5 mg dose, 2.5% on 10 mg, and 3.1% on 15 mg, compared with 1% on placebo. Those are severe GI events broadly, nausea, vomiting, diarrhea and the like, not gastroparesis specifically. Gastroparesis never got its own adverse-reaction rate in the trials.

Why the FDA’s disclaimer language matters here

Some context on how the FDA handles postmarketing reports generally. In September 2023, the agency added ileus to the semaglutide (Ozempic) label based on voluntarily reported adverse events. The FDA was explicit: because these reports come from a population of unknown size, it’s “not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure.” That same disclaimer language still appears in the current Zepbound label’s postmarketing section. It’s a standing caveat on all postmarketing data, not something specific to gastroparesis.

The bottom line

The FDA label doesn’t say GLP-1 or GIP drugs cause gastroparesis. It says they’re not recommended if you already have severe gastroparesis, and separately, that they slow stomach emptying as part of how they work. The one study with real numbers behind it is a claims-database analysis in semaglutide users without diabetes: low absolute risk, elevated relative risk against two specific alternatives. We could not verify a distinct March 2026 FDA gastroparesis warning from any primary source. Treat that claim as unconfirmed until it shows up on fda.gov.

If you’re managing GI side effects on a GLP-1, it’s worth understanding how these drugs affect the rest of your body, including muscle loss during rapid weight loss. And if cost shapes which drug or formulation you choose, see our breakdowns of tirzepatide cost and semaglutide cost per month.

Frequently Asked Questions

Did the FDA issue a new gastroparesis-specific warning for GLP-1 drugs in March 2026? We couldn’t verify this. No primary FDA source, fda.gov or accessdata.fda.gov, confirms a March 2026 gastroparesis-specific labeling action. The Zepbound label we reviewed directly shows a 02/2026 revision to its “Severe Gastrointestinal Adverse Reactions” section, but the underlying “not recommended in patients with severe gastroparesis” sentence is pre-existing language, not new text added in that revision. Claims describing a March 14, 2026 mandate with a June 15, 2026 compliance deadline trace back to no FDA source we could find. Treat that date as unconfirmed.

Does the FDA label say GLP-1 drugs cause gastroparesis? No. The label says the drugs are “not recommended in patients with severe gastroparesis,” a caution about people who already have the condition. Separately, it notes the drugs pharmacologically “delay gastric emptying,” an effect that’s largest after the first dose and fades over time. Gastroparesis is not listed in the label as a confirmed, drug-caused adverse reaction with an estimated incidence.

How much does semaglutide actually increase gastroparesis risk based on real evidence? The best available evidence is one retrospective claims-database study, not an FDA finding, comparing semaglutide to two other obesity treatments in people without diabetes. Absolute incidence ran low across all groups: 6.5 per 1,000 person-years with semaglutide versus 2.1 with bupropion-naltrexone and 1.1 with sleeve gastrectomy. The relative risk was higher, with adjusted hazard ratios of 3.33 and 6.14 against those two comparators. Both numbers matter. The relative risk is real, but the absolute chance of it happening to any one person stayed low in this dataset.

What should someone on Ozempic, Wegovy, Mounjaro, or Zepbound do if they suspect gastroparesis symptoms? Follow the Medication Guide. Report severe or persistent GI symptoms, nausea, vomiting, or feeling full unusually fast, to your healthcare provider. Disclose any pre-existing severe gastroparesis before starting the medication. And disclose GLP-1 or GIP use before any procedure involving anesthesia or deep sedation, since Section 5.9 of the Zepbound label flags unresolved questions about fasting and aspiration risk in this situation. This is general patient education, not a substitute for talking to your provider.

This article is for informational purposes only and is not medical advice. Talk to your healthcare provider before starting, stopping, or changing any medication.